Recent Updates
Recently added Catalysts
SANA Negative Sentiment Score: 25/100

Sana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA

Key Takeaway: Sana Biotechnology, Inc. is embroiled in a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to assist investors who suffered losses from alleged securities fraud between March 17, 2023, and November 4, 2024. The complaint asserts that company officials made misleading statements regarding the company's financial health and the status of its product candidates. Key allegations include insufficient funding to support ongoing operations, potential cuts to product development, and overstated financial capabilities. Investors may contact Levi & Korsinsky to learn about their rights and potential compensation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sana Biotechnology is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit raises concerns about the company's financial stability and ability to fund its operations.
  • There are claims that the company's product candidates are less promising than previously stated, leading to potential funding cuts.
  • The lawsuit suggests that public statements made by the defendants were materially false and misleading.

Full Press Release Details

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:
SANA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against Sana Biotechnology about?

The lawsuit seeks to recover losses for investors impacted by alleged securities fraud.

What are the key claims in the Sana Biotechnology lawsuit?

The lawsuit alleges false statements regarding financial stability and product prospects.

How can I join the class action lawsuit?

Investors must request to be appointed as lead plaintiff by May 20, 2025.

Will participating in the lawsuit cost me anything?

No, class members may be entitled to compensation without any out-of-pocket costs.

Who should I contact for more information?

Investors can contact Joseph E. Levi at jlevi@levikorsinsky.com.

Last updated: Apr 21, 2025